Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...
Some of the newest and most exciting gene therapy technologies share a problem: They’re too bulky. They rely on multiple functional DNA and protein elements that must reach target cells all at the ...
There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College of Medicine and the UMass Chan Medical School have achieved ...
The special properties of methylcellulose foam could make it a vehicle for bedside genetic engineering, according to a proof-of-principle study from bioengineers at Fred Hutch Cancer Center. In the ...
VIRxSYS (www.virxsys.com) is developing a unique technology that is advancing both gene therapy and HIV treatment. VRX496 uses a lentiviral vector to deliver a payload to block the replication of HIV.
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...
Gene therapy is defined as the treatment of disease by transfer of genetic material into cells, to prevent, treat and potentially even cure a disease. Gene therapies can work by several mechanisms: 1) ...
Platform has the capability to reduce time from process development to GMP by 55 percent and deliver a drug product in fewer than 8 months nAAVigation platform will be launched at the Cell & Gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback